Cofoe Medical Technology (301087) Q1 2025 earnings summary

Executive summary

• Q1 revenue fell 8.59% YoY to ¥737.79 million; net income attributable to shareholders declined 9.68% to ¥91.43 million, while adjusted net income excluding non-recurring items fell 25.34% to ¥68.52 million.

• Acquisition-related costs and a subsidiary disposal affected reported expenses and investment income; operating cash flow also weakened materially YoY.

Financial highlights

• Revenue was ¥737.79 million, down from ¥807.15 million YoY; total operating costs were ¥646.33 million versus ¥676.81 million.

• Net income attributable to shareholders was ¥91.43 million, down 9.68% YoY; net income excluding non-recurring items was ¥68.52 million, down 25.34%.

• Non-recurring gains totaled ¥22.90 million; net income attributable to shareholders was ¥91.43 million compared with ¥101.22 million a year earlier.

• Other income rose to ¥27.28 million from ¥6.31 million, mainly due to increased government-grant-related income.

Key financial ratios and metrics

• Basic EPS was ¥0.45 versus ¥0.50 YoY; diluted EPS was ¥0.45 versus ¥0.49.

• Weighted average return on equity was 1.89%, down 0.16 percentage points YoY.

• Total assets were ¥6.42 billion, down 0.07% from year-end; equity attributable to shareholders was ¥4.89 billion, up 2.02%.